A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

Blood
Francesco PassamontiMario Lazzarino

Abstract

Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV, we found that leukocytosis leukocyte count>(15x10(9)/L) at diagnosis is a risk factor for the evolution of post-PV MF. In a series of 68 patients who developed post-PV MF, median survival was 5.7 years. Hemoglobin level less than 100 g/L (10 g/dL) at diagnosis of post-PV MF was an independent risk factor for survival. The course of post-PV MF, however, is a dynamic process that implies a progressive worsening of clinical parameters. Using a multivariate Cox proportional hazard regression with time-dependent covariates, we found that a dynamic score based on hemoglobin level less than 100 g/L (10 g/dL), platelet count less than 100x10(9)/L, and leukocyte count more than 30x10(9)/L is useful to predict survival at any time from diagnosis of post-PV MF. The resulting hazard ratio of the score was 4.2 (95% CI: 2.4-7.7; P<.001), meaning a 4.2-fold worsening of survival for each risk factor acquired during follow up. In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of pos...Continue Reading

References

Jun 1, 1997·British Journal of Haematology·F CervantesE Montserrat
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Aug 16, 2003·Blood·H Joachim DeegFrederick R Appelbaum
Nov 16, 2004·The American Journal of Medicine·Francesco PassamontiMario Lazzarino
Jul 7, 2007·British Journal of Haematology·Naseema GangatAyalew Tefferi
Aug 23, 2007·Blood·Giovanni BarosiUNKNOWN Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis

❮ Previous
Next ❯

Citations

Jan 1, 2009·Current Hematologic Malignancy Reports·Francesco Passamonti
May 15, 2013·International Journal of Hematology·Neha BhagwatPriya Koppikar
Sep 3, 2010·La Presse médicale·Laurent Savale, Olivier Sitbon
Jun 22, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Leonardo BoiocchiAttilio Orazi
Jul 7, 2012·Blood·Nikolaos PapadantonakisKatya Ravid
Jan 2, 2009·Haematologica·Francesco Passamonti, Elisa Rumi
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Holly Geyer, Ruben A Mesa
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Amy Zhou, Stephen T Oh
Sep 30, 2014·Current Hematologic Malignancy Reports·Robyn M ScherberRuben A Mesa
Dec 14, 2011·Leukemia·F Passamonti
Dec 19, 2012·Leukemia & Lymphoma·Brady L SteinAlison R Moliterno
Mar 14, 2013·Expert Opinion on Pharmacotherapy·Benjamin HensleyRuben Mesa
Feb 1, 2009·Expert Review of Hematology·Alessandro M VannucchiAlberto Bosi
Jul 15, 2015·Expert Opinion on Emerging Drugs·Holly L Geyer, Ruben A Mesa
Feb 20, 2016·Current Hematologic Malignancy Reports·Andreas Reiter, Claire Harrison
Sep 27, 2012·Hematology/oncology Clinics of North America·Francesco PassamontiDomenica Caramazza
Jun 30, 2012·Medicina clínica·Ana Esther Kerguelén FuentesAna Rodriguez de la Rúa
May 15, 2012·Leukemia Research·Chad CheringtonRuben A Mesa
Apr 3, 2012·Hematology/oncology Clinics of North America·Marina KremyanskayaRonald Hoffman
Jul 17, 2009·British Journal of Haematology·Alberto Alvarez-LarránCarles Besses
Jul 2, 2009·Journal of Thrombosis and Haemostasis : JTH·F PassamontiM Lazzarino
Feb 14, 2009·European Journal of Haematology·Kebede HusseinAyalew Tefferi
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·John Mascarenhas, Ronald Hoffman
Oct 5, 2015·Clinical Lymphoma, Myeloma & Leukemia·Shireen SirhanVikas Gupta
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Erik Vakil, Ayalew Tefferi
Nov 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Haefaa AlchalbyUNKNOWN Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Nov 20, 2014·Annals of Hematology·Mario TiribelliRenato Fanin
May 23, 2012·Blood·Francesco Passamonti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.